A quality improvement strategy can improve electronic health record-based screening for depression and anxiety in people with epilepsy.

The FDA has approved Brekiya (dihydroergotamine mesylate) injection for the acute treatment of migraine with or without aura and the acute treatment of cluster headaches in adults.

The FDA has approved Imaavy™ (nipocalimab-aahu) for the treatment of generalized myasthenia gravis in patients aged 12 years and older who are AChR or anti-muscle-specific tyrosine kinase antibody ...

Both mild and moderate-to-severe psoriasis are significantly associated with an increased risk for sleep disorders.

For US adult cancer survivors with a new alcohol use disorder diagnosis, the 1-year cumulative incidence of treatment initiation was 14.3%.

Nontraumatic subarachnoid hemorrhage remains one of the most common cardiovascular and neurological causes of death and disabilities in the world.

A scientific statement has been published by the American Heart Association regarding the effect of sleep health on cardiometabolic health.

Spinal cord stimulation can reduce pain and restore nerve function among patients with diabetic peripheral neuropathy.

There are few sex differences in narcolepsy type 1 symptom onset, but women have longer sleep times, higher efficiency, and men have higher BMI.

Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep ...

Central hypersomnolence disorders, such as narcolepsy type 2 and idiopathic hypersomnia, are associated with reduced health-related quality of life.

Patients with Alzheimer disease and cognitive impairment with delayed REM sleep patterns have increased levels of brain amyloid and tau.